Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
By D. Strumberg, H. Richly, R. Hilger, N. Schleucher, S. Korfee, M. Tewes, Markus Faghih, E. Brendel, D. Voliotis, C. Haase and 5 more. Journal of Clinical Oncology, 2005
865 citations recorded by the source corpus.
Subfields: Molecular Biology, Plant Science
View Paper: https://www.semanticscholar.org/paper/2924769e2576352460c1bc4859613a5bff603600
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Role of Tyrosine Kinase Inhibitors in Cancer Therapy (2005, background): “Although originally developed as a Raf kinase inhibitor, it was subsequently found to inhibit a variety of kinase receptors, including VEGFR, EGFR, and PDGFR kinases (Wilhelm et al., 2004; Strumberg et al., 2005).”
- Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis (2014, neutral): “DOI: 10.7554/eLife.02523 17 of 25 Research article from 5.2–21 μM (Awada et al., 2005; Strumberg et al., 2005).”
- Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (2006, background): “Notable grade 3/4 adverse events included fatigue, diarrhea, and HFS, which are commonly associated with sorafenib.(11) The interpatient PK differences between CP A and B patients were not clinically relevant, because sorafenib was equally well tolerated by these two subgroups, and exposure values w”
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis (2006, background): “Sorafenib monotherapy has been shown to have a manageable side effect profile in Phase I/II/III studies (Strumberg et al, 2003, 2005; Ratain et al, 2004, 2006; Awada et al, 2005; Escudier et al, 2005).”
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (2006, background): “A total of four single-agent Phase I trials, evaluating sorafenib oral doses ranging up to 800 mg twice daily (bid), have now been completed and publishe”